Agios Pharmaceuticals (AGIO) Non-Current Assets (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Non-Current Assets data on file, last reported at $390.8 million in Q2 2026.

• Quarterly Non-Current Assets fell 13.51% year-over-year to $390.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.4 billion (down 40.96% YoY) and the FY2025 annual result came in at $355.2 million, down 49.09% from the prior year.
• Non-Current Assets grew to $390.8 million in Q2 2026, from $350.1 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $717.6 million in Q3 2024 to a low of $103.3 million in Q4 2023.
• A 5-year average of $381.5 million and a median of $360.2 million in 2022 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2023 — Non-Current Assets tumbled 74.56% — and 2024, when it soared 575.42%.
• Tracing AGIO's Non-Current Assets over 5 years: stood at $405.9 million in 2022, then tumbled by 74.56% to $103.3 million in 2023, then soared by 575.42% to $697.6 million in 2024, then sank by 49.09% to $355.2 million in 2025, then climbed by 10.02% to $390.8 million in 2026.
• The last three Non-Current Assets figures came in at $390.8 million (Q2 2026), $350.1 million (Q1 2026), and $355.2 million (Q4 2025), per Business Quant data.